This most recent twist inside the Lykos Therapeutics saga threatens a major overhaul of the company’s strategy and course, with Musk ally and billionaire investor Antonio Gracias showing up to desire to choose the corporate back towards its nonprofit drug advancement roots and a far more Doblinite philosophy.In several respects, the for-revenue c